September 15, 2010 — Forest Pharmaceuticals Inc.
Forest Pharmaceuticals Inc. (FPI), a subsidiary of New York-based Forest Laboratories, has agreed to pay more than $313 Million to settle qui tam actions filed against them by private relators.
The allegations asserted against FPI were that FPI began distributing the drug Levothroid without first obtaining FDA approval, and that FPI promoted use of the drug Celexa to treat children and adolescents despite the fact that Celexa had not been approved for pediatric use.
As a reward for having filed their qui tam claims, the private relators will receive approximately $14 Million.
See U.S. Dept of Justice Press Release 09/15/10